Deutsche Bank AG Invests $5.63 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Deutsche Bank opened a new BioCryst Pharmaceuticals position worth approximately $5.63 million, acquiring 563,361 shares, while institutional investors collectively own 85.88% of the company.
• BioCryst reported stronger-than-expected quarterly results, with earnings of $0.30 per share versus the $0.15 consensus estimate and revenue of $218.25 million, up 33.6% year over year.
• Analyst sentiment is broadly positive: eight analysts rate BCRX a Buy and four a Hold, producing a “Moderate Buy” consensus and an average price target of $20.60 versus the recent $9.68 share price.

Deutsche Bank AG bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 563,361 shares of the biotechnology company's stock, valued at approximately $5,634,000. Deutsche Bank AG owned 0.22% of BioCryst Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Royal Bank of Canada raised its position in BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after buying an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of BioCryst Pharmaceuticals by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company's stock valued at $1,019,000 after acquiring an additional 8,517 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company's stock valued at $14,490,000 after acquiring an additional 640,704 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company's stock worth $3,363,000 after acquiring an additional 47,355 shares during the period. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.68 on Tuesday. The business's 50 day moving average price is $9.64 and its 200-day moving average price is $8.97. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -6.45 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm's revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.15 EPS. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several recent research reports. Cantor Fitzgerald raised their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a report on Tuesday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Citizens Jmp lifted their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a "market outperform" rating in a research note on Thursday, May 7th. Finally, Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source